Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Cholangiocarcinoma × RRx-001 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomatitis 2 Mucositis 2 Mouth Neoplasms 2 Head and Neck Neoplasms 2 Neuroendocrine Tumors 1 Lung Neoplasms 1 Colorectal Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Squamous Cell 1 Carcinoma, Small Cell 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Gemcitabine 52 Cisplatin 29 Oxaliplatin 24 Fluorouracil 19 lenvatinib 18 durvalumab 18 Capecitabine 16 Leucovorin 13 pembrolizumab 9 apatinib 9 tislelizumab 7 sintilimab 6 pemigatinib 6 Radiotherapy 6 Panitumumab 6 Floxuridine 6 Albumin-Bound Paclitaxel 6 tremelimumab 5 olaparib 5 Taxes 5 Specimen Handling 5 Magnetic Resonance Spectroscopy 5 Folfox protocol 5 Drug Therapy 5 Bevacizumab 5 camrelizumab 4 Nivolumab 4 Irinotecan 4 Carboplatin 4 Biopsy 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02452970 2024-04-24

EPIC

EpicentRx, Inc.

Phase 2 Terminated

4 enrolled 6 charts

Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡